-
公开(公告)号:KR100758317B1
公开(公告)日:2007-09-13
申请号:KR1020060039225
申请日:2006-05-01
Applicant: 한국과학기술연구원
IPC: A61K31/5375 , A61P9/04
CPC classification number: A61K31/5375
Abstract: A composition for blocking T-type calcium channel comprising morpholin-2-one derivatives is provided to block the T-type calcium channel in the same level as the conventional T-type calcium channel blocker, mibefradil, without side effects. A composition for blocking T-type calcium channel comprises morpholin-2-one derivatives represented by the formula(1), or pharmaceutically acceptable salts thereof, wherein R^1 and R^2 are each independently hydrogen, C1-C6 alkyl, C1-C6 cycloalkyl, or phenyl optionally substituted by halogen, nitro, hydroxyl or C1-C6 alkoxy; and R^3 and R^4 are each independently hydrogen, C1-C6 alkyl, C1-C6 thioalkyl, amino or phenyl optionally substituted by halogen, nitro, hydroxyl or C1-C6 alkoxy. The composition prevents or treats diseases caused by overexpression of T-type calcium channel including angina pectoris, hypertension, myocardiac infarction, pain and epilepsy.
Abstract translation: 提供一种用于阻断包含吗啉-2-酮衍生物的T型钙通道的组合物,以阻断与常规T型钙通道阻滞剂米非司酮相同水平的T型钙通道,无副作用。 用于阻断T型钙通道的组合物包括由式(1)表示的吗啉-2-酮衍生物或其药学上可接受的盐,其中R 1和R 2各自独立地为氢,C 1 -C 6烷基, C 6环烷基或任选被卤素,硝基,羟基或C 1 -C 6烷氧基取代的苯基; R 3和R 4各自独立地为氢,C 1 -C 6烷基,C 1 -C 6硫代烷基,任选被卤素,硝基,羟基或C 1 -C 6烷氧基取代的氨基或苯基。 该组合物预防或治疗由过度表达T型钙通道引起的疾病,包括心绞痛,高血压,心肌梗塞,疼痛和癫痫。